Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $302000.0.

  • C4 Therapeutics' Capital Expenditures rose 242307.69% to $302000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $482000.0, marking a year-over-year increase of 16195.65%. This contributed to the annual value of $180000.0 for FY2024, which is 8946.14% down from last year.
  • Per C4 Therapeutics' latest filing, its Capital Expenditures stood at $302000.0 for Q3 2025, which was up 242307.69% from -$4000.0 recorded in Q4 2024.
  • In the past 5 years, C4 Therapeutics' Capital Expenditures registered a high of $3.1 million during Q2 2022, and its lowest value of -$13000.0 during Q3 2024.
  • Its 5-year average for Capital Expenditures is $597533.3, with a median of $362000.0 in 2023.
  • In the last 5 years, C4 Therapeutics' Capital Expenditures plummeted by 10254.78% in 2024 and then surged by 242307.69% in 2025.
  • Quarter analysis of 5 years shows C4 Therapeutics' Capital Expenditures stood at $109000.0 in 2021, then soared by 1266.97% to $1.5 million in 2022, then plummeted by 89.46% to $157000.0 in 2023, then tumbled by 102.55% to -$4000.0 in 2024, then surged by 7650.0% to $302000.0 in 2025.
  • Its last three reported values are $302000.0 in Q3 2025, -$4000.0 for Q4 2024, and -$13000.0 during Q3 2024.